Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity

Simple item page
dc.contributor.authorPawelec, Graham
dc.contributor.authorVerschoor, Chris P
dc.contributor.authorOstrand-Rosenberg, Suzanne
dc.date.accessioned2019-11-15T16:46:10Z
dc.date.available2019-11-15T16:46:10Z
dc.date.issued2019-05-15
dc.description.abstractSince the realization that immature myeloid cells are powerful modulators of the immune response, many studies on “myeloid-derived suppressor cells” (MDSCs) have documented their ability to promote tumor progression in melanoma and other cancers. Whether MDSCs are induced solely pathologically in tumorigenesis, or whether they also represent physiological immune control mechanisms, is not well-understood, but is particularly important in the light of ongoing attempts to block their activities in order to enhance anti-tumor immunity. Here, we briefly review studies which explore (1) how best to identify MDSCs in the context of cancer and how this compares to other conditions in humans; (2) what the suppressive mechanisms of MDSCs are and how to target them pharmacologically; (3) whether levels of MDSCs with various phenotypes are informative for clinical outcome not only in cancer but also other diseases, and (4) whether MDSCs are only found under pathological conditions or whether they also represent a physiological regulatory mechanism for the feedback control of immunity. Studies unequivocally document that MDSCs strongly influence cancer outcomes, but are less informative regarding their relevance to infection, autoimmunity, transplantation and aging, especially in humans. So far, the results of clinical interventions to reverse their negative effects in cancer have been disappointing; thus, developing differential approaches to modulate MSDCs in cancer and other diseases without unduly comprising any normal physiological function requires further exploration.en_US
dc.description.urihttps://www.frontiersin.org/articles/10.3389/fimmu.2019.01099/fullen_US
dc.format.extent10 pagesen_US
dc.genrejournal articlesen_US
dc.identifierdoi:10.13016/m2ceqk-wday
dc.identifier.citationPawelec G, Verschoor CP and Ostrand-Rosenberg S (2019) Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity. Front. Immunol. 10:1099. doi: 10.3389/fimmu.2019.01099en_US
dc.identifier.urihttps://doi.org/10.3389/fimmu.2019.01099
dc.identifier.urihttp://hdl.handle.net/11603/16331
dc.language.isoen_USen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.isAvailableAtThe University of Maryland, Baltimore County (UMBC)
dc.relation.ispartofUMBC Biological Sciences Department Collection
dc.relation.ispartofUMBC Faculty Collection
dc.rightsThis item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
dc.rightsAttribution 4.0 International (CC BY 4.0)*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectMDSCen_US
dc.subjectcancer immunityen_US
dc.subjectobesityen_US
dc.subjectautoimmunityen_US
dc.subjectagingen_US
dc.subjecttransplantationen_US
dc.subjectinfectious diseaseen_US
dc.titleMyeloid-Derived Suppressor Cells: Not Only in Tumor Immunityen_US
dc.typeTexten_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fimmu-10-01099.pdf
Size:
1.1 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.56 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

UMBC Biological Sciences Department
UMBC Faculty Collection